Compile Data Set for Download or QSAR
maximum 50k data
Found 34 of ic50 for UniProtKB: P09086
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM335495((2R,5S,13aR)—N-(2-chloro-4-fluorobenzyl)-8-hy...)
Affinity DataIC50:  42nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM330054((2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-(2,4,5-trifluor...)
Affinity DataIC50:  94nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM330049((13aS)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzy...)
Affinity DataIC50:  137nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM448201(US10689399, Compound 40)
Affinity DataIC50:  204nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM350693(US9795602, Compound 29)
Affinity DataIC50:  216nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM330039((2R,5S,13aR)-N-(2,4-difluorobenzyl)-8-hydroxy-7,9-...)
Affinity DataIC50:  240nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM330040((2S,5R,13aS)-N-(2,4-difluorobenzyl)-8-hydroxy-7,9-...)
Affinity DataIC50:  250nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM448200(US10689399, Compound 39)
Affinity DataIC50:  358nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM448216(US10689399, Compound 100)
Affinity DataIC50:  450nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM330052((1R,4S,12aS)-7-hydroxy-6,8-dioxo-N-(2,4,6-trifluor...)
Affinity DataIC50:  476nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM330048((2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluor...)
Affinity DataIC50:  487nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM448198(US10689399, Compound 13)
Affinity DataIC50:  610nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM448213(US10689399, Compound 96)
Affinity DataIC50:  1.36E+3nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM330060((1R,3S,4R,12aR)-7-hydroxy-3-methyl-6,8-dioxo-N-(2,...)
Affinity DataIC50:  1.51E+3nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM330041( (4R,12aS)-N-(1-(2,4-difluorophenyl)cyclopropyl)-7...)
Affinity DataIC50:  2.23E+3nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM350694(US9795602, Compound 58)
Affinity DataIC50:  2.49E+3nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM350830(US9795602, Compound 59)
Affinity DataIC50:  2.51E+3nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM330047((1R,4S,12aR)-7-hydroxy-6,8-dioxo-N-(2,4,6-trifluor...)
Affinity DataIC50:  2.82E+3nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM330059((1S,4R,12aR)-3,3-difluoro-7-hydroxy-6,8-dioxo-N-(2...)
Affinity DataIC50:  3.73E+3nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM330055((1R,4S,12aR)-7-hydroxy-6,8-dioxo-N—((R)-1-(2,...)
Affinity DataIC50:  3.83E+3nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM330051((1S,4R,12aS)-N-(2,4-difluorobenzyl)-7-hydroxy-6,8-...)
Affinity DataIC50:  4.91E+3nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM330050((1R,4S,12aR)-N-(2,4-difluorobenzyl)-7-hydroxy-6,8-...)
Affinity DataIC50:  6.20E+3nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM350834(US9795602, Compound 12)
Affinity DataIC50:  6.40E+3nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM330057((1S,4R,12aS)-3,3-difluoro-7-hydroxy-6,8-dioxo-N-(2...)
Affinity DataIC50:  1.00E+4nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM330056((1S,3R,4R,12aR)-3-fluoro-7-hydroxy-6,8-dioxo-N-(2,...)
Affinity DataIC50:  1.00E+4nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM350831(US9795602, Compound 31)
Affinity DataIC50:  1.00E+4nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM350832(US9795602, Compound 32)
Affinity DataIC50:  1.00E+4nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM350833(US9795602, Compound 39)
Affinity DataIC50:  1.00E+4nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM330044( (2S,5R)-N—((S)-1-(2,4-difluorophenyl)-2,2,2-...)
Affinity DataIC50:  1.00E+4nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM330042((2S,5R,13aS)-N—((R)-1-(2,4-difluorophenyl)eth...)
Affinity DataIC50:  1.00E+4nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM350836(US9795602, Compound 28)
Affinity DataIC50:  1.00E+4nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM350835(US9795602, Compound 25b)
Affinity DataIC50:  1.00E+4nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM50576849(CHEMBL4876008)
Affinity DataIC50: >5.00E+4nMAssay Description:Inhibition of OCT2 (unknown origin) expressed in HEK293 cellsMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM50228403((R)-8-(3-aminopiperidin-1-yl)-7-(but-2-ynyl)-3-met...)
Affinity DataIC50:  8.00E+4nMAssay Description:Inhibition of OCT2 (unknown origin) expressed in HEK293 cells assessed as reduction of [14C]metformin substrate uptake at 100 uM by liquid scintillat...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed